This product is a second-generation cephalosporin for intravenous or intramuscular injection. It has a wider antibacterial spectrum against Gram-negative bacilli than the first-generation cephalosporins. It has good antibacterial activity similar to cefoxitin against Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Citrobacter, Providencia and Enterobacter, but its activity against indole-positive Proteus, Morganella, Providencia and some Klebsiella is lower than that of cefoxitin. It has satisfactory activity against gonococci of influenza bacilli, including beta-lactamase-producing strains. Like other second-generation cephalosporins, Pseudomonas, Serratia and Acinetobacter are resistant to this product. This product is effective against most Gram-positive cocci. Its activity against Staphylococcus aureus is similar to that of cefoxitin and cefuroxime, but lower than that of cefoxitin, cephalothin and cefazolin. 90% of the strains can be inhibited by this product at a concentration of 4.0 to 8.3 mg/L. Most streptococci, including Streptococcus pneumoniae, Streptococcus pyogenes and Group B Streptococcus, are sensitive to this product. Staphylococcus epidermidis is relatively resistant to this product. Streptococcus faecalis, Staphylococcus aureus and methicillin-resistant strains of Staphylococcus epidermidis are all resistant to this product. The activity of this product against anaerobic bacteria has not been well studied, and Bacteroides fragilis is resistant to this product. The minimum bactericidal concentration (MBC) of this product for Staphylococcus aureus, Group B Streptococcus and Escherichia coli is significantly higher than its minimum inhibitory concentration (MIC). This product is very stable to type I beta-lactamase, but can be slowly hydrolyzed by type IIIa, IIIb and V beta-lactamase, while only type IV beta-lactamase is sensitive.

It can promote the functional recovery of central nervous system damage caused by various reasons. The mechanism of action is to promote neural reconstruction (including the survival of nerve cells, axon growth and synapse formation). It has a protective effect on secondary neurodegeneration after injury. After application, it can improve cerebral hemodynamic parameters and reduce brain edema after injury. It can reduce nerve cell edema by improving the activity of cell membrane enzymes. Animal experiments have shown that it can improve behavioral disorders caused by Parkinson's disease.

It can promote the functional recovery of central nervous system damage caused by various reasons, promote neural reconstruction (including the survival of nerve cells, axon growth and synapse formation), protect secondary neurodegeneration after injury, improve cerebral hemodynamic parameters and reduce brain edema after injury, and reduce nerve cell edema by improving the activity of cell membrane enzymes. Animal experiments have shown that it can improve behavioral disorders caused by Parkinson's disease

It can promote functional recovery of central nervous system damage caused by various reasons, including promoting the survival of nerve cells, axon growth and synapse formation; it has a protective effect on secondary neurodegeneration after injury; it improves cerebral hemodynamic parameters and brain edema after injury; it reduces nerve cell edema by improving the activity of cell membrane enzymes; animal experiments have shown that it can improve behavioral disorders caused by Parkinson's disease.

It can promote functional recovery of central nervous system damage caused by various reasons, promote neural reconstruction (including the survival of nerve cells, axon growth and synapse formation), protect against secondary neurodegeneration after injury, improve cerebral hemodynamic parameters and brain edema after injury, and reduce nerve cell edema by improving the activity of cell membrane enzymes. Animal experiments have shown that it can improve behavioral disorders caused by Parkinson's disease.